852329-66-9

Basic information

• Product Name: Dutogliptin
• Synonyms: Dutogliptin;[(2R)-1-[[(3R)-3-Pyrrolidinylamino]acetyl]-2-pyrrolidinyl]-boronic acid;((R)-1-(((R)-pyrrolidin-3-yl)glycyl)pyrrolidin-2-yl)boronic acid;Boronic acid, B-[(2R)-1-[2-[(3R)-3-pyrrolidinylamino]acetyl]-2-pyrrolidinyl]-
• CAS NO: 852329-66-9
• Molecular Formula: C₁₀H₂₀BN₃O₃
• Molecular Weight: 241.0951
• Mol File: 852329-66-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 494.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• PKA: 9.71±0.20(Predicted)
• CAS DataBase Reference: Dutogliptin(CAS DataBase Reference)
• NIST Chemistry Reference: Dutogliptin(852329-66-9)
• EPA Substance Registry System: Dutogliptin(852329-66-9)

Safety Data

• Hazardous Substances Data: 852329-66-9(Hazardous Substances Data)

Usage

General Description

Dutogliptin is a chemical compound classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is used in the treatment of type 2 diabetes. By inhibiting the DPP-4 enzyme, dutogliptin helps to increase the levels of incretin hormones in the body, which in turn stimulates the release of insulin and reduces the production of glucose by the liver. This mechanism of action helps to regulate blood sugar levels and improve glycemic control in individuals with type 2 diabetes. Dutogliptin is taken orally in the form of a tablet and is often used in combination with other medications for the management of diabetes. It is still in the investigational stage and has not yet been approved for clinical use.

Upstream product

• 1056211-06-3 3-(R)-(benzyloxycarbonyl-carboxymethyl-amino)-pyrrolidine-1-carboxylic acid benzyl ester 
• 923566-03-4 (2R)-1-{2-[(3R)-pyrrolidinylamino]-acetyl}-pyrrolidine-2-boronic acid (1S,2S,3R,5S)-pinanediol ester 

Downstream Products

• 890402-81-0 dutogliptin-L-tartrate 

Relevant articles and documents

Pyrrolidine ester dipeptidyl peptidase inhibitors and its pharmaceutical composition

The invention relates to pyrrolidine ester (boronate ester) DDP - IV inhibitors, dipeptidyl peptidase - IV participation in diseases such as diabetes in particular 2 type diabetes, tumor or other treatment and prevention of disease in a useful role. This invention relates to pharmaceutical compositions comprising these compounds and in the prevention or treatment of dipeptidyl peptidase - IV in these diseases.

HETEROCYCLIC BORONIC ACID COMPOUNDS

Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C (CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form a fused cyclopropyl; and optionally, one of the bonds in the ring containing X is a double bond; and CriRii, R1, R1, R3, R4 and R5 are as described herein. Methods for preparing these compounds, and methods for treating diabetes, especially Type II diabetes, and other related diseases are described using the compounds of formula I in pharmaceutical compositions which contain these compounds. Pharmaceutical compositions which contain combinations of these compounds with other antidiabetic agents are also described herein.